Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Everest Files IND for China Phase III Trial of Novel Antibiotic

publication date: Jun 12, 2018

Everest Medicines, a US-China startup that in-licenses drugs for China's market, filed an IND to start a Phase III clinical trial of eravacycline in complicated intra-abdominal infections (cIAI). In February, Everest acquired greater China rights to eravacycline in a $43.5 million deal ($7 million upfront) from Tetraphase Pharma of the US. Founded in 2017, Everest began operations with a $50 million investment from C-Bridge Capital, the first tranche of an initial round expected to raise $130 million. More details....

Stock Symbol: (NSDQ: TTPH)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.